Humacyte Shares Drop 6% After Offering Announcement

Announcement

Humacyte Inc (NASDAQ:HUMA), a commercial‑stage biotechnology company, announced that it has commenced an underwritten public offering of its common stock, with all shares being sold by the company itself.

Offering Details

Barclays, BTIG and Titan Partners (a division of American Capital Partners) are serving as joint book‑running managers. The offering includes a 30‑day option for the underwriters to purchase up to an additional 15% of the shares sold in the offering. The offering remains subject to market conditions, and the company provides no assurance regarding completion or the final terms of the transaction.

Use of Proceeds

Humacyte stated that the net proceeds will be used to fund the commercialization of Symvess, its first FDA‑approved product that launched in the United States in the first quarter of 2025; to support a planned Biologics License Application supplement filing for a hemodialysis indication; to advance development of other pipeline product candidates; and for working capital and general corporate purposes.

Market Reaction

Following the announcement, Humacyte’s shares fell approximately 6% in after‑hours trading on Wednesday.